Glucokinase activators effectively manage PP blood sugar in diabetes but with hypoglycemia risk: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-10-27 03:30 GMT | Update On 2021-10-27 03:30 GMT

China: A recent study in the journal Medicine has shown glucokinase activators (GKAs) to be more effective than placebo for postprandial blood sugar control in patients with type 2 diabetes mellitus (T2DM). However, the use of GKAs were associated with a comparatively higher risk of hypoglycemia.

Glucokinase activators are a novel family of glucose-lowering agents used for treating patients with type 2 diabetes. In these patients, GKAs has been shown to reduce blood sugar levels. Through a meta-analysis, Qian Gao, Affiliated Hospital of Shaoxing University of Edocrine and Metabolism Department, Zhejiang, China, and colleagues aimed to compare the efficacy/safety of GKAs in patients with T2DM.

The researchers searched the online databases for articles published before December 30, 2020. A total of 4 articles (5 studies) were included in the meta-analysis.

The study yielded the following findings:

GKAs were associated with reductions in glycated hemoglobin levels from baseline (WMD, −0.3%).
No significant difference between GKA and placebo treatment was observed in the results of fasting plasma glucose levels from baseline (WMD 0.013 mmol/L).
A significantly higher change in 2-hour postprandial plasma glucose (2-h PPG) levels (WMD −2.434 mmol/L) was observed following GKA than placebo treatment.
GKAs were associated with a higher prevalence of causing hypoglycemic events than placebo treatment (risk difference [RD], 0.06).
GKAs had no association with the risk of developing adverse effects (RD, 0.038) and serious adverse events (RD, 0.01).

The researchers concluded by saying that in patients with T2DM, glucokinase activators (GKAs) were more effective than placebo treatment for postprandial blood glucose control. In addition, GKAs had a comparably high risk of causing hypoglycemia. However, this new class of hypoglycemic agents needs continued evaluation in RCTs to ascertain long-term efficacy and safety.

Reference:

Gao, Qian MM∗; Zhang, Wenjun MD; Li, Tingting MM; Yang, Guojun MM; Zhu, Wei MD; Chen, Naijun MD; Jin, Huawei MD The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus, Medicine: October 08, 2021 - Volume 100 - Issue 40 - p e27476 doi: 10.1097/MD.0000000000027476

Article Source : Medicine journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Glucokinase activators effectively manage PP blood sugar in diabetes but with hypoglycemia risk: Study

Similar News

BMI and Waist Circumference Show Mixed Links to Diabetic Complications in Type 2 Diabetes, Study Finds

Time-Restricted Eating Matches Calorie Restriction in Reducing Liver Fat in MASLD, Study Finds

More Microvascular Complications Raise Heart and Death Risk in Diabetes, reveals study

Lipid Accumulation Product strongest Predictor of Diabetes Among Visceral Obesity Indices: Study

Tirzepatide Tied to Lower Risk of Erectile Dysfunction in Men with Type 2 Diabetes: Study Reveals

Osteosarcopenia in Prediabetic Adults Linked to Nearly 3-Fold Higher Osteoarthritis Risk: NHANES Study

Medical Bulletin 05/Jul/2025

Investigational GLP-1 Receptor Agonist effective in Lowering HbA1c in Early Type 2 Diabetes: NEJM